Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis.

Lebwohl, MG ;
Sugarman, JL ;
Gold, LS ;
Pariser, DM ;
Lin, T ;
Pillai, R ;
Martin, G ;
Harris, S ;
Israel, R

Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: lebwohl@aol.com. University of California, San Francisco, California. Henry Ford Hospital, Detroit, Michigan. Virginia Clinical Research Inc, Norfolk, Virginia. Ortho Dermatologics, Bridgewater, New Jersey. Dow Pharmaceutical Sciences Inc (division of Valeant Pharmaceuticals, North America LLC), Petaluma, California. Valeant Pharmaceuticals, Bridgewater, New Jersey.

Journal of the American Academy of Dermatology. 2019;(1):282-285

Full text from:

Elsevier Science
Ovid Technologies, Inc.

Methodological quality

Publication Type : Clinical Trial ; Multicenter Study

Metadata

MeSH terms : Psoriasis

Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis.

Other resources

Methodological quality

Metadata